Skip to main content

Rituximab‐induced serum sickness in refractory immune thrombocytopenic purpura

Buy Article:

$51.00 plus tax (Refund Policy)


Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti‐CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1‐20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab‐induced serum sickness.

Keywords: immune thrombocytopenic purpura; rituximab; serum sickness

Document Type: Research Article


Affiliations: Department of Internal Medicine, Hotel-Dieu, CHU, Clermont-Ferrand, France

Publication date: 2011-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more